The US government has reached a deal with pharmaceutical companies Novo Nordisk and Eli Lilly to significantly reduce the prices of obesity drugs sold on the Trump website, from at least $1,000 to around $350. This move aims to make these medications more accessible to those in need. The impact on the pharmaceutical industry and the healthcare market is expected to be substantial.